Adamas Pharmaceuticals Inc (ADMS) Stock
ADMS is no longer traded. Adamas Pharmaceuticals was delisted from the Nasdaq in November 2021.
Prices on this page are historical; the last trade was November 23, 2021 at $8.22.
Adamas Pharmaceuticals stock price history
ADMS final trading statistics
- Final close
- $8.22
- Final trading day
- Nov 23, 2021
- Market cap at delisting
- $376.37M
- Shares outstanding
- 45.79M
- Final 52-week range
- $4.02 – $9.15
- Avg. volume (final 3 mo.)
- 1,263,101
- All-time high (split-adj.)
- $42.65 · Jan 2018
- All-time low (split-adj.)
- $1.99 · Mar 2020
- Return since IPO
- -41.3%
- Beta
- 2.82
- Book value / share
- $0.13
- Price / book
- 62.75
Adamas Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $74.46M | -$57.4M | -$2.02 |
| FY2019 | $54.64M | -$105.2M | -$3.80 |
| FY2018 | $34.05M | -$131.0M | -$4.89 |
| FY2017 | $571.0K | -$89.5M | -$3.97 |
| FY2016 | $572.0K | -$60.1M | -$2.77 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. As of November 24, 2021, Adamas Pharmaceuticals, Inc. operates as a subsidiary of Supernus Pharmaceuticals, Inc.
Adamas Pharmaceuticals stock FAQ
What happened to Adamas Pharmaceuticals stock?
Adamas Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $8.22 on November 23, 2021.
Is ADMS stock still trading?
No. ADMS was delisted from the Nasdaq in November 2021 and no longer trades on a U.S. exchange.
What was the last price of ADMS stock?
ADMS closed at $8.22 on its final trading day, November 23, 2021, for a market value of about $376.37M.
What were Adamas Pharmaceuticals's revenue and earnings in its last full fiscal year?
Adamas Pharmaceuticals reported revenue of $74.46M and net income of -$57.4M in fiscal 2020, its last full year as a public company.
When did Adamas Pharmaceuticals go public?
Adamas Pharmaceuticals Inc stock began trading on April 10, 2014.